AACR 2021: Copanlisib-rituximab combination cuts lymphoma progression or death by nearly half in CHRONOS-3 trial
A combination of copanlisib and rituximab led to a 48 percent reduction in the risk…
A combination of copanlisib and rituximab led to a 48 percent reduction in the risk…
Sets of genes associated with resistance to immunotherapy in patients with metastatic urothelial cancer of…
Compared with available standard therapies, including immune checkpoint inhibitors, treatment with the bispecific fusion protein…
Peter Mac researchers feature in this week’s American Association of Cancer Research program, which is…
Immunotherapy together with an experimental cancer drug could offer a new way of treating some…